Department of Biological Sciences and Center for Biotechnology Research in UBITA, Konkuk University, Seoul 143-701, Korea.
Arch Pharm Res. 2011 Nov;34(11):1799-816. doi: 10.1007/s12272-011-1103-2. Epub 2011 Dec 3.
The study of cytochrome P450 pharmacogenomics is of particular interest because of its promise in the development of rational means to optimize drug therapy with respect to patient's genotype to ensure maximum efficacy with minimal adverse effects. Drug metabolizing P450 enzymes are polymorphic and are the main phase I enzymes responsible for the metabolism of clinical drugs. Therefore, polymorphisms in the P450s have the most impact on the fate of clinical drugs in phase I metabolism since almost 80% of drugs in use today are metabolized by these enzymes. Predictive genotyping for P450 enzymes for a more effective therapy will be routine for specific drugs in the future. In this review, we discuss the current knowledge of polymorphic metabolism by functional alterations in nonsynonymous SNPs of P450 1A2, 2A6, 2C8, 2C9, 2C19, 2D6, and 3A4 enzymes.
细胞色素 P450 药物基因组学的研究特别有趣，因为它有望通过患者基因型来优化药物治疗，以确保最大疗效和最小不良反应，从而提供合理的方法。药物代谢 P450 酶是多态性的，是负责临床药物代谢的主要 I 相酶。因此，P450 中的多态性对 I 相代谢中临床药物的命运影响最大，因为目前使用的几乎 80%的药物都是由这些酶代谢的。对 P450 酶进行预测性基因分型，以便对特定药物进行更有效的治疗，将成为未来的常规做法。在这篇综述中，我们讨论了 P450 1A2、2A6、2C8、2C9、2C19、2D6 和 3A4 酶中非同义 SNP 导致功能改变的多态性代谢的最新知识。
